Publicação
Antibody-Conjugated Nanoparticles for Therapeutic Applications
| Resumo: | A great challenge to clinical development is the delivery of chemotherapeutic agents, known to cause severe toxic effects, directly to diseased sites which increase the therapeutic index whilst minimizing off-target side effects. Antibody-conjugated nanoparticles offer great opportunities to overcome these limitations in therapeutics. They combine the advantages given by the nanoparticles with the ability to bind to their target with high affinity and improve cell penetration given by the antibodies. This specialized vehicle, that can encapsulate several chemotherapeutic agents, can be engineered to possess the desirable properties, allowing overcoming the successive physiological conditions and to cross biological barriers and reach a specific tissue or cell. Moreover, antibody-conjugated nanoparticles have shown the ability to be internalized through receptor-mediated endocytosis and accumulate in cells without being recognized by the P-glycoprotein, one of the main mediators of multi-drug resistance, resulting in an increase in the intracellular concentration of drugs. Also, progress in antibody engineering has allowed the manipulation of the basic antibody structure for raising and tailoring specificity and functionality. This review explores recent developments on active drug targeting by nanoparticles functionalized with monoclonal antibodies (polymeric micelles, liposomes and polymeric nanoparticles) and summarizes the opportunities of these targeting strategies in the therapy of serious diseases (cancer, inflammatory diseases, infectious diseases, and thrombosis). |
|---|---|
| Autores principais: | Cardoso, Maria Margarida Canas Mendes de Almeida |
| Outros Autores: | Peça, Inês N.; Roque, Ana Cecília Afonso |
| Assunto: | infectious diseases therapy tumour therapy inflammatory diseases therapy targeted drug delivery antibody-conjugated nanoparticles surfacemodification Active targeting Active targeting antibody-conjugated nanoparticles infectious diseases therapy inflammatory diseases therapy; surface modification targeted drug delivery tumour therapy SDG 3 - Good Health and Well-being |
| Ano: | 2012 |
| País: | Portugal |
| Tipo de documento: | recensão |
| Tipo de acesso: | acesso aberto |
| Instituição associada: | Universidade Nova de Lisboa |
| Idioma: | inglês |
| Origem: | Repositório Institucional da UNL |
| _version_ | 1879446835930595328 |
|---|---|
| author | Cardoso, Maria Margarida Canas Mendes de Almeida |
| author2 | Peça, Inês N. Roque, Ana Cecília Afonso |
| author2_role | author author |
| author_facet | Cardoso, Maria Margarida Canas Mendes de Almeida Peça, Inês N. Roque, Ana Cecília Afonso |
| author_role | author |
| contributor_name_str_mv | DQ - Departamento de Química CQFB-REQUIMTE - Centro de Química Fina e Biotecnologia (Lab. Associado REQUIMTE) Bentham Science Publishers RUN |
| country_str | PT |
| creators_json_txt | [{\"Person.name\":\"Cardoso, Maria Margarida Canas Mendes de Almeida\"},{\"Person.name\":\"Peça, Inês N.\"},{\"Person.name\":\"Roque, Ana Cecília Afonso\"}] |
| datacite.contributors.contributor.contributorName.fl_str_mv | DQ - Departamento de Química CQFB-REQUIMTE - Centro de Química Fina e Biotecnologia (Lab. Associado REQUIMTE) Bentham Science Publishers RUN |
| datacite.creators.creator.creatorName.fl_str_mv | Cardoso, Maria Margarida Canas Mendes de Almeida Peça, Inês N. Roque, Ana Cecília Afonso |
| datacite.date.Accepted.fl_str_mv | 2012-01-01T00:00:00Z |
| datacite.date.available.fl_str_mv | 2017-05-17T10:27:43Z |
| datacite.date.embargoed.fl_str_mv | 2017-05-17T10:27:43Z |
| datacite.rights.fl_str_mv | http://purl.org/coar/access_right/c_abf2 |
| datacite.subjects.subject.fl_str_mv | infectious diseases therapy tumour therapy inflammatory diseases therapy targeted drug delivery antibody-conjugated nanoparticles surfacemodification Active targeting Active targeting antibody-conjugated nanoparticles infectious diseases therapy inflammatory diseases therapy; surface modification targeted drug delivery tumour therapy SDG 3 - Good Health and Well-being |
| datacite.titles.title.fl_str_mv | Antibody-Conjugated Nanoparticles for Therapeutic Applications |
| dc.contributor.none.fl_str_mv | DQ - Departamento de Química CQFB-REQUIMTE - Centro de Química Fina e Biotecnologia (Lab. Associado REQUIMTE) Bentham Science Publishers RUN |
| dc.creator.none.fl_str_mv | Cardoso, Maria Margarida Canas Mendes de Almeida Peça, Inês N. Roque, Ana Cecília Afonso |
| dc.date.Accepted.fl_str_mv | 2012-01-01T00:00:00Z |
| dc.date.available.fl_str_mv | 2017-05-17T10:27:43Z |
| dc.date.embargoed.fl_str_mv | 2017-05-17T10:27:43Z |
| dc.format.none.fl_str_mv | application/pdf |
| dc.identifier.none.fl_str_mv | http://hdl.handle.net/10362/20689 |
| dc.language.none.fl_str_mv | eng |
| dc.rights.none.fl_str_mv | http://purl.org/coar/access_right/c_abf2 |
| dc.subject.none.fl_str_mv | infectious diseases therapy tumour therapy inflammatory diseases therapy targeted drug delivery antibody-conjugated nanoparticles surfacemodification Active targeting Active targeting antibody-conjugated nanoparticles infectious diseases therapy inflammatory diseases therapy; surface modification targeted drug delivery tumour therapy SDG 3 - Good Health and Well-being |
| dc.title.fl_str_mv | Antibody-Conjugated Nanoparticles for Therapeutic Applications |
| dc.type.none.fl_str_mv | http://purl.org/coar/resource_type/c_efa0 |
| description | A great challenge to clinical development is the delivery of chemotherapeutic agents, known to cause severe toxic effects, directly to diseased sites which increase the therapeutic index whilst minimizing off-target side effects. Antibody-conjugated nanoparticles offer great opportunities to overcome these limitations in therapeutics. They combine the advantages given by the nanoparticles with the ability to bind to their target with high affinity and improve cell penetration given by the antibodies. This specialized vehicle, that can encapsulate several chemotherapeutic agents, can be engineered to possess the desirable properties, allowing overcoming the successive physiological conditions and to cross biological barriers and reach a specific tissue or cell. Moreover, antibody-conjugated nanoparticles have shown the ability to be internalized through receptor-mediated endocytosis and accumulate in cells without being recognized by the P-glycoprotein, one of the main mediators of multi-drug resistance, resulting in an increase in the intracellular concentration of drugs. Also, progress in antibody engineering has allowed the manipulation of the basic antibody structure for raising and tailoring specificity and functionality. This review explores recent developments on active drug targeting by nanoparticles functionalized with monoclonal antibodies (polymeric micelles, liposomes and polymeric nanoparticles) and summarizes the opportunities of these targeting strategies in the therapy of serious diseases (cancer, inflammatory diseases, infectious diseases, and thrombosis). |
| dirty | 0 |
| eu_rights_str_mv | openAccess |
| format | review |
| fulltext.url.fl_str_mv | https://run.unl.pt/bitstreams/c04457d6-e6f1-4923-90fd-5c8c101a671f/download |
| funder_facet_str_mv | FCT{{{_:::_}}}Fundação para a Ciência e a Tecnologia FCT{{{_:::_}}}Fundação para a Ciência e a Tecnologia |
| funding.funder.alternateName_str_mv | FCT FCT |
| funding.funder.identifier_str_mv | http://doi.org/10.13039/501100001871 http://doi.org/10.13039/501100001871 |
| funding.funder.name_str_mv | Fundação para a Ciência e a Tecnologia Fundação para a Ciência e a Tecnologia |
| funding.identifier_str_mv | SFRH/BD/48773/2008 PEst-C/EQB/LA0006/2011 |
| funding.name_str_mv | 6820 - DCRRNI ID |
| funding_str_mv | SFRH/BD/48773/2008 info:eu-repo/grantAgreement/FCT//SFRH%2FBD%2F48773%2F2008/PT PEst-C/EQB/LA0006/2011 info:eu-repo/grantAgreement/FCT/6820 - DCRRNI ID/PEst-C%2FEQB%2FLA0006%2F2011/PT |
| id | run_a48add129ca5cdca986be7e50d0a6afc |
| identifier.url.fl_str_mv | http://hdl.handle.net/10362/20689 |
| inst_facet_str | urn:organizationAcronym:unl{{{_:::_}}}Universidade Nova de Lisboa |
| instacron_str | unl |
| institution | Universidade Nova de Lisboa |
| instname_str | Universidade Nova de Lisboa |
| language | eng |
| network_acronym_str | run |
| network_name_str | Repositório Institucional da UNL |
| oai_identifier_str | oai:run.unl.pt:10362/20689 |
| organization_str_mv | urn:organizationAcronym:unl |
| person_str_mv | Cardoso, Maria Margarida Canas Mendes de Almeida Peça, Inês N. Roque, Ana Cecília Afonso |
| publishDate | 2012 |
| repo_facet_str | urn:repositoryAcronym:run{{{_:::_}}}Repositório Institucional da UNL |
| reponame_str | Repositório Institucional da UNL |
| repository_id_str | urn:repositoryAcronym:run |
| service_str_mv | urn:repositoryAcronym:run |
| spelling | engenA great challenge to clinical development is the delivery of chemotherapeutic agents, known to cause severe toxic effects, directly to diseased sites which increase the therapeutic index whilst minimizing off-target side effects. Antibody-conjugated nanoparticles offer great opportunities to overcome these limitations in therapeutics. They combine the advantages given by the nanoparticles with the ability to bind to their target with high affinity and improve cell penetration given by the antibodies. This specialized vehicle, that can encapsulate several chemotherapeutic agents, can be engineered to possess the desirable properties, allowing overcoming the successive physiological conditions and to cross biological barriers and reach a specific tissue or cell. Moreover, antibody-conjugated nanoparticles have shown the ability to be internalized through receptor-mediated endocytosis and accumulate in cells without being recognized by the P-glycoprotein, one of the main mediators of multi-drug resistance, resulting in an increase in the intracellular concentration of drugs. Also, progress in antibody engineering has allowed the manipulation of the basic antibody structure for raising and tailoring specificity and functionality. This review explores recent developments on active drug targeting by nanoparticles functionalized with monoclonal antibodies (polymeric micelles, liposomes and polymeric nanoparticles) and summarizes the opportunities of these targeting strategies in the therapy of serious diseases (cancer, inflammatory diseases, infectious diseases, and thrombosis).application/pdfenAntibody-Conjugated Nanoparticles for Therapeutic ApplicationsCardoso, Maria Margarida Canas Mendes de AlmeidaPeça, Inês N.Roque, Ana Cecília AfonsoDQ - Departamento de QuímicaCQFB-REQUIMTE - Centro de Química Fina e Biotecnologia (Lab. Associado REQUIMTE)Bentham Science PublishersHostingInstitutionOrganizationalRUNe-mailmailto:run@unl.ptrun@unl.ptISSNIsPartOf0929-8673URNIsPartOfPURE: 354774URNIsPartOfPURE UUID: 11e89a88-bba9-4a3c-a534-54d62cf1557aURNIsPartOfresearchoutputwizard: 33132URNIsPartOfWOS: 000305945800003URNIsPartOfScopus: 84863641507URNIsPartOfPubMed: 22612698DOIIsPartOf10.2174/0929867128007846672017-05-17T10:27:43Z20122012-01-01T00:00:00ZHandlehttp://hdl.handle.net/10362/20689http://purl.org/coar/access_right/c_abf2open accessinfectious diseases therapytumour therapyinflammatory diseases therapytargeted drug deliveryantibody-conjugated nanoparticlessurfacemodificationActive targetingActive targetingantibody-conjugated nanoparticlesinfectious diseases therapyinflammatory diseases therapy;surface modificationtargeted drug deliverytumour therapySDG 3 - Good Health and Well-being1187653 bytesFundação para a Ciência e a TecnologiaDRUG DELIVERY: DEVELOPMENT OF TARGETED FUNCTIONAL PARTICLES FOR CANCER THERAPYinfo:eu-repo/grantAgreement/FCT//SFRH%2FBD%2F48773%2F2008/PTSFRH/BD/48773/2008Crossref Funder IDhttp://doi.org/10.13039/501100001871Fundação para a Ciência e a TecnologiaStrategic Project - LA 6 - 2011-2012info:eu-repo/grantAgreement/FCT/6820 - DCRRNI ID/PEst-C%2FEQB%2FLA0006%2F2011/PTPEst-C/EQB/LA0006/20116820 - DCRRNI IDCrossref Funder IDhttp://doi.org/10.13039/501100001871other research producthttp://purl.org/coar/resource_type/c_efa0reviewhttp://purl.org/coar/access_right/c_abf2application/pdffulltexthttps://run.unl.pt/bitstreams/c04457d6-e6f1-4923-90fd-5c8c101a671f/download |
| spellingShingle | Antibody-Conjugated Nanoparticles for Therapeutic Applications Cardoso, Maria Margarida Canas Mendes de Almeida infectious diseases therapy tumour therapy inflammatory diseases therapy targeted drug delivery antibody-conjugated nanoparticles surfacemodification Active targeting Active targeting antibody-conjugated nanoparticles infectious diseases therapy inflammatory diseases therapy; surface modification targeted drug delivery tumour therapy SDG 3 - Good Health and Well-being |
| status | SINGLETON |
| subject.fl_str_mv | infectious diseases therapy tumour therapy inflammatory diseases therapy targeted drug delivery antibody-conjugated nanoparticles surfacemodification Active targeting Active targeting antibody-conjugated nanoparticles infectious diseases therapy inflammatory diseases therapy; surface modification targeted drug delivery tumour therapy SDG 3 - Good Health and Well-being |
| title | Antibody-Conjugated Nanoparticles for Therapeutic Applications |
| title_full | Antibody-Conjugated Nanoparticles for Therapeutic Applications |
| title_fullStr | Antibody-Conjugated Nanoparticles for Therapeutic Applications |
| title_full_unstemmed | Antibody-Conjugated Nanoparticles for Therapeutic Applications |
| title_short | Antibody-Conjugated Nanoparticles for Therapeutic Applications |
| title_sort | Antibody-Conjugated Nanoparticles for Therapeutic Applications |
| topic | infectious diseases therapy tumour therapy inflammatory diseases therapy targeted drug delivery antibody-conjugated nanoparticles surfacemodification Active targeting Active targeting antibody-conjugated nanoparticles infectious diseases therapy inflammatory diseases therapy; surface modification targeted drug delivery tumour therapy SDG 3 - Good Health and Well-being |
| topic_facet | infectious diseases therapy tumour therapy inflammatory diseases therapy targeted drug delivery antibody-conjugated nanoparticles surfacemodification Active targeting Active targeting antibody-conjugated nanoparticles infectious diseases therapy inflammatory diseases therapy; surface modification targeted drug delivery tumour therapy SDG 3 - Good Health and Well-being |
| url | http://hdl.handle.net/10362/20689 |
| visible | 1 |